IL17A and psoriasis: A preclinical study on an imiquimod-induced murine psoriasis model showed that both oral and topical application of dihydromyricetin, a plant-derived flavonoid, significantly suppresses IL-17 production by pathogenic Th-17 cells and decreases circulating IL-17 levels through direct binding to RORγt protein and reducing its nuclear translocation (Table 2) [136].